BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36720762)

  • 21. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
    J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.
    Parekh C; Jubran R; Erdreich-Epstein A; Panigrahy A; Bluml S; Finlay J; Dhall G
    J Neurooncol; 2011 Jul; 103(3):673-80. PubMed ID: 21038110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
    Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
    Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
    van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
    Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group.
    Müller K; Schlamann A; Guckenberger M; Warmuth-Metz M; Glück A; Pietschmann S; Wawer A; Kortmann RD; Kramm C; von Bueren AO
    Strahlenther Onkol; 2014 Apr; 190(4):377-81. PubMed ID: 24638239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
    Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Pediatric Low-Grade Gliomas.
    Sait SF; Giantini-Larsen AM; Tringale KR; Souweidane MM; Karajannis MA
    Curr Neurol Neurosci Rep; 2023 Apr; 23(4):185-199. PubMed ID: 36881254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.
    Seidel C; von Bueren AO; Bojko S; Hoffmann M; Pietsch T; Gielen GH; Warmuth-Metz M; Bison B; Kortmann RD; Kramm CM
    Strahlenther Onkol; 2018 Mar; 194(3):215-224. PubMed ID: 29022050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric high-grade glioma: moving toward subtype-specific multimodal therapy.
    Chatwin HV; Cruz Cruz J; Green AL
    FEBS J; 2021 Nov; 288(21):6127-6141. PubMed ID: 33523591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
    Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
    J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features and outcomes of pediatric intracranial gliomas: results from single center's 226 cases and corroborated with SEER database.
    Chen Z; Guo Z; Wang J; Cao D; Xu Y; Dong F; Wan F
    Childs Nerv Syst; 2023 Mar; 39(3):593-601. PubMed ID: 36662273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
    Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
    J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab for the treatment of high-grade glioma.
    Khasraw M; Simeonovic M; Grommes C
    Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.
    Hummel TR; Chow LM; Fouladi M; Franz D
    Paediatr Drugs; 2013 Feb; 15(1):29-42. PubMed ID: 23329387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
    Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
    J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
    Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
    J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric low-grade glioma in the era of molecular diagnostics.
    Ryall S; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2020 Mar; 8(1):30. PubMed ID: 32164789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
    Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
    J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.